IP Library Granted Patent US 7,098,030
Granted Patent B2
US 7,098,030 · App. 10/899,509 · Granted Aug 29, 2006

Polyampholytes for delivering polyions to a cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,098,030
App. No.
10/899,509
Granted
Aug 29, 2006
Kind
B2
Abstract

An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.

Claims (22)

1. A process for enhancing delivery of a polynucleotide into a cell, comprising:

a) forming a complex of polyampholyte containing a cleavable bond, wherein said bond is cleavable by a decrease in pH, and the polynucleotide; and,

b) delivering the complex to a cell.

2. The process of claim 1 wherein the polyampholyte contains maleamic acid.

3. The process of claim 1 wherein the polyampholyte is membrane-disruptive upon cleavage.

4. The process of claim 1 wherein the polynucleotide is delivered to a cell in vivo.

5. The process of claim 1 wherein the polynucleotide comprises an siRNA.

6. The process of claim 1 wherein the polynucleotide comprises an expression cassette encoding an siRNA.

7. The process of claim 1 wherein the polyampholyte comprises one or more polynucleotides covalently linked to a polycation.

8. The process of claim 7 wherein the polynucleotide is linked to the polycation via a labile linkage.

9. The process of claim 8 wherein the labile linkage consists of a disulfide bond.

10. The process of claim 7 wherein the polynucleotide comprises an siRNA.

11. A complex for delivering a polynucleotide to a cell, comprising: the polynucleotide and a cleavable polyampholyte wherein the polyion and the cleavable polyampholyte are bound in complex.

12. The complex of claim 11 wherein the cleavable polyampholyte contains maleamic acid.

13. The complex of claim 11 wherein the cleavable polyampholyte is membrane-disruptive upon cleavage.

14. The complex of claim 11 wherein the polynucleotide comprises an siRNA.

15. A composition for delivering a polyion to a cell comprising: the polyion linked to a second polyion of opposite charge to form a polyampholyte.

16. The composition of claim 15 wherein the linkage consists of a labile linkage.

17. The composition of claim 16 wherein the labile linkage consists of a disulfide bond.

18. The composition of claim 16 wherein the labile linkage consists of a bond that is cleavable by a decrease in pH.

19. The composition of claim 15 where the polyion consists of a polynucleotide.

20. The composition of claim 19 where the polynucleotide consists of an siRNA.

Assignments (3)
CHANGE OF NAME Recorded Feb 26, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032302/0843 →
CHANGE OF NAME Recorded Apr 6, 2009
From: MIRUS BIO CORPORATION
To: ROCHE MADISON INC.
Reel/Frame 022629/0791 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2006
From: ROZEMA, DAVID B.; HAGSTROM, JAMES E.; BUDKER, VLADIMIR FOR BUDKER, TATYANA PERSONAL REPRESENTATIVE; TRUBETSKOY, VLADIMIR; WOLFF, JON A.; MONAHAN, SEAN D.; SLATTUM, PAUL M.
To: MIRUS BIO CORPORATION
Reel/Frame 018270/0479 →